En­laza launch­es with $61M, aims to take co­va­len­cy in­to pro­tein drugs

Co­va­lent small mol­e­cule drug de­vel­op­ment has seen a bit of a re­nais­sance in re­cent years. But a new San Diego-based biotech wants to take co­va­len­cy one step fur­ther — in­to pro­tein drugs.

En­laza Ther­a­peu­tics launched out of stealth Thurs­day morn­ing with $61 mil­lion in fund­ing. The round was led by Aval­on Ven­tures, fol­lowed by Light­speed Ven­ture Part­ners, Fra­zier Life Sci­ences and Sam­sara Bio­Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER